Severe enteropathy with villous atrophy olmesartan medoxomil-associated;Entéropathie sévère avec atrophie villositaire associée à la prise d’olmésartan médoxomil

Therapie

Volumn 68, Issue 6, 2013, Pages 419-421

  Nunge, Débora ^a   Eoche, Matthieu ^a   Fumery, Mathurin ^a   Nguyen Khac, Eric ^a   Gras, Valérie ^a   Andréjak, Michel ^a,b  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

Diarrhea; Olmesartan medoxomil; Sprue; Villous atrophy

Indexed keywords

AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATROPHY; DIARRHEA; FEMALE; HUMANS; IMIDAZOLES; INTESTINAL DISEASES; MICROVILLI; SEVERITY OF ILLNESS INDEX; TETRAZOLES;

OLMESARTAN;

CASE REPORT; CELIAC DISEASE; DIAGNOSTIC TEST; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTEROPATHY; HISTOPATHOLOGY; HUMAN; LETTER; PRIORITY JOURNAL; SEROLOGY;

EID: 84891513507     PISSN: 00405957     EISSN: 19585578     Source Type: Journal    
DOI: 10.2515/therapie/2013057     Document Type: Letter

References (13)

1. Rubio-Tapia A, Herman ML, Ludvigsson JF, etal. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 2012; 87: 732-8
2. Research C for DE and. Drug safety and availability - FDA drug safety communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. http://www.fda.gov/Drugs/DrugSafety/ucm359477.htm
3. ANSM. Cas graves d’entéropathies associés avec l’olmésartan médoxomil -Point d’information - ANSM. Agence nationale de sécurité du médicament et des produits de santé 2013. http://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Cas-graves-d-enteropathies-associes-avec-l-olmesartan-medoxomil-Point-d-information
4. Stanich PP, Yearsley M, Meyer MM. Olmesartan-associated sprue-like enteropathy. J Clin Gastroenterol 2013 Nov-Dec; 47(10):894-5, doi: 10.1097/MCG.0b013e31829a27e6
5. DeGaetani M, Tennyson CA, Lebwohl B. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am J Gastroenterol 2013; 108: 647-53
6. Tkoub EM. Maladie coeliaque de l’adulte. Rev Française Allergol Immunol Clin 2008; 48, Supplement 1: S27-S31
7. Lebwohl B, Rubio-Tapia A, Assiri A, et al. Diagnosis of celiac disease. Gastrointest Endosc Clin N Am 2012; 22: 661-77
8. Dreifuss SE, Tomizawa Y, Farber NJ, et al. Spruelike enteropathy associated with olmesartan: an unusual case of severe diarrhea. Case Reports Gastrointest Med 2013;2013:618071
9. Rubio-Tapia A, Herman ML, Ludvigsson JF. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 2012; 87: 732-8
10. Talbot GH. Small bowel histopathologic findings suggestive of celiac disease in an asymptomatic patient receiving olmesartan. Mayo Clin Proc 2012; 87: 1231-2
11. Hansson T, Ulfgren A-K, Lindroos E, et al. Transforming growth factor-p (TGF-p) and tissue transglutaminase expression in the small intestine in children with coeliac disease. Scand J Immunol 2002; 56: 530-7
12. Menne J, Haller H. Olmesartan and intestinal adverse effects in the ROADMAP study. Mayo Clin Proc 2012; 87: 1230-1
13. Rubio-Tapia A, Herman ML, Murray JA. In reply. Mayo Clin Proc 2012; 87: 1232